Relationship of Acylcarnitines to Myocardial Ischemic Remodeling and Clinical Manifestations in Chronic Heart Failure.
Yuriy Nikitich BelenkovAnton A AgeevMaria V KozhevnikovaNatalia V KhabarovaAnastasia V KrivovaEkaterina O KorobkovaLudmila V PopovaAlexey V EmelyanovSvetlana A AppolonovaNatalia E MoskalevaKsenia M ShestakovaElena V PrivalovaPublished in: Journal of cardiovascular development and disease (2023)
ACs may be used in assessing the severity of the clinical manifestations and MR. ACs are an important locus to study in terms of altered metabolic pathways in patients with CHF of ischemic etiology and SD. Further larger prospective trials are warranted and needed to determine the potential benefits to treat patients with CV diseases with aberrate AC levels.